Latest news with #psychedelictherapy
CBC
5 days ago
- Climate
- CBC
What questions do you have as wildfires burn across Canada?
You've got smart questions, we've got solid answers. Click here to listen to the CBC's Just Asking every Saturday at 4 p.m. when you need to make sense of the world around you. Let your friend Saroja Coelho be your guide. With guest experts, Just Asking turns the week's news and latest trends into tips that help you make better decisions in your life. Whether it's tech, money, career or health — we'll hear you out, and help you out. The show takes live calls on CBC Radio every Saturday afternoon, and drops the podcast that same evening. Here's what's happening this Saturday: What questions do you have as wildfires burn across Canada? Both Manitoba and Saskatchewan are in a state of emergency as communities across Canada are witnessing the effects of wildfires - from Newfoundland and Labrador, to northern Ontario to B.C. Early signs point to another active wildfire season in 2025 after Canada just experienced two of its worst wildfire seasons on record. Lori Daniels is the Koerner Chair in Wildfire Coexistence in the Faculty of Forestry at UBC. Anabela Bonada is the Managing Director of Climate Science at the Intact Centre on Climate Adaptation. What questions do you have about psychedelic therapy? There's a growing body of research pointing to the therapeutic applications for psychedelics, including MDMA and psilocybin, along with ketamine which was approved for therapeutic use in 2020. The promise of a new frontier in treatment for depression, anxiety and PTSD is an appealing one for researchers and patients desperately looking for solutions in a mental health crisis. But with all the excitement around psychedelics in therapy, where does the research stand, and what risks should patients be aware of? Leah Mayo is an Assistant Professor in the Department of Psychiatry at the University of Calgary and the Parker Research Chair in Psychedelics. Ron Shore is the Interim Assistant Scientific Director of the Canadian Institute of Military and Veteran Health Research and an Assistant Professor in the Department of Psychiatry, at Queen's University in Kingston. They'll take your questions!
Associated Press
5 days ago
- General
- Associated Press
Legislators, Advocates, Lawyers, and Organizers Take the Stage during Policy Track at Psychedelic Science 2025 to Shape the Future of Psychedelic Reform
DENVER, May 30, 2025 (GLOBE NEWSWIRE) -- In the last year, we've seen the first-ever FDA review of psychedelic-assisted therapy and state legislatures debating—and passing—bills to create legal access across the country. As momentum for psychedelic policy reform continues to grow, Psychedelic Science 2025 (PS2025) will convene the world's leading voices to reflect on lessons learned, assess today's political landscape, and chart a course for just, compassionate, and responsible psychedelic policy. Hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), this global conference takes place June 16–20, 2025, at the Colorado Convention Center in Denver. Psychedelic Science is the largest psychedelic conference in the world — and this year, its Policy Track stands out as one of the most dynamic forums to discuss the urgent need to create legal access to psychedelic substances, drive drug law reforms, and the transition away from criminalization. Despite the challenges of the last two years, the field of psychedelic policy reform is more dynamic than ever, and it is imperative that it builds toward a future where psychedelic therapies are responsibly integrated into society in a way that repairs, instead of reinforces, cracks in existing social and political systems. In 2023, we set the groundwork — this year, the Policy track is about weaving together modern evidence, traditional practices, and practical approaches in service of a stronger safety net and more responsible ecosystem. These conversations are about more than just the law — they are about community, healing, and justice. Our speakers will offer technical expertise alongside essential wisdom on how we can change the world without leaving these values behind. — Ismail L. Ali, J.D., Interim MAPS Co-Executive Director From high-ranking government officials to grassroots organizers, speakers on PS2025's Policy Track will highlight the rapidly evolving intersection of psychedelic research, public opinion, and the law. For policymakers, lawyers, researchers, activists, clergy, Tribal and Indigenous leadership, and community advocates shaping the future of the psychedelic landscape, Psychedelic Science 2025's Policy track offers: The overarching theme of the Policy Track is 'Psychedelic Policy at a Crossroads – Law, Liberty, and Global Change.' It examines how psychedelic research and advocacy are reshaping law and society from multiple angles: Sessions include: Behind the Scenes of Getting Congress Behind Psychedelic Research – As multipartisan momentum builds in Congress, this session spotlights the groundbreaking work of the Congressional Psychedelics Advancing Clinical Treatments (PACT) Caucus and the recently introduced VA bill to establish psychedelic research centers. Join Melissa Lavasani (Founder, Psychedelic Medicine Coalition) and Amy Rising (Air Force Veteran) as they discuss their work to drive progress in Congress, why the PACT Caucus was created, and how several years of careful listening and relationship-building have led to federal support for psychedelic-assisted therapies. From Right to Try to Rescheduling: Legal Battles to Expand Psychedelic Access – Groundbreaking public-interest litigation has catalyzed drug policy reform from the beginning. In this session, pioneering drug policy reform advocate Ethan Nadelmann (Founder, Drug Policy Alliance), and renowned attorneys Kathryn Tucker (Special Counsel, Emerge Law Group) and Shane Pennington (Counsel, Vicente LLP) share updates on high-profile lawsuits aimed at forcing the DEA to ease federal restrictions on research and access to care. The discussion will illuminate how strategic court challenges are pushing the boundaries of current law — and potentially opening new pathways for psychedelic-assisted care through the judiciary. The National Psychedelic Landscape: An Overview of Past, Current, and Future Policy Reform – Over the past 18 months, lawmakers in dozens of states have introduced psychedelic legislation, but why do some bills succeed while others stall? Led by Sam Chapman (of Toolbox Strategies; formerly the Executive Director of Healing Advocacy Fund), this session analyzes the political and practical lessons from psychedelic policy efforts across the country. Chapman will break down which state programs are gaining traction (and why), which have faltered, and who the key players are in advancing or obstructing reform. By distilling trends from dozens of bills — from modest research committees to ambitious regulated access programs — this presentation will point to the possibility of a unified national strategy to advance psychedelic access in diverse political climates. Legislative Success in New Mexico: How It Happened – In a historic move, New Mexico became the first state to pass a regulated access program for psychedelic therapy through its legislature in 2025. This session brings together key players behind the effort – Senator Jeff Steinborn (D-NM), Dominick Zurlo (Division Director, Medical Cannabis Program, New Mexico's Department of Health), and Adele Getty (Advocate and Director, Limina Foundation) – to share the untold story of how diverse stakeholders came together to shape and pass this precedent-setting legislation. Attendees will gain behind-the-scenes insight into coalition building, evidence-based education, implementation strategies that brought the bill to life – along with the challenges and lessons learned for future state-level reform. Nevada's Blueprint for Psychedelic Reform: A Bipartisan Model for Cultural and Legislative Change – As psychedelic reform gains momentum, Nevada is pioneering a unique approach that could inspire other states. Kate Cotter (Executive Director, Nevada Coalition for Psychedelic Medicines), Jon Dalton (Co-Founder and President, Nevada Coalition for Psychedelic Medicines), and Diane Goldstein (a retired police lieutenant and Executive Director of Law Enforcement Action Partnership) will reveal how unlikely allies joined forces in Nevada to advance safe, regulated access to psychedelics. From forging coalitions across the political spectrum to integrating grassroots support, they'll share successes and challenges from Nevada's journey — and how to balance advocacy and education in a way that can drive reform in other states. Indigenous Leadership and Healing in the Natural Medicine Movement – Psychedelic policy is not just about science and law; it's also about honoring the cultures that have stewarded sacred medicines for generations. Regina Randall (Founder and Chair of the Alaska Entheogenic Awareness Council), along with Indigenous leaders and advocates David Karabelnikoff and Richard Porter (Executive Director, Knik Tribe) will explore the intersection of indigenous knowledge and modern psychedelic policy reform, particularly focusing on the work being done in Alaska to decriminalize entheogenic plant medicines and establish a regulated medical access framework. This session will examine the vital role of Indigenous communities in shaping policy and ensuring that psychedelic practices respect traditional teachings - even while working within the constraints of the existing political system. Keeping Young People Safer in an Increasingly Post-Prohibition World — As psychedelics emerge from the underground into mainstream awareness, how do we keep young people informed, empowered, and safe? This dynamic panel combines established experts with emerging voices to trace the evolution of psychedelic public education: from DARE to Safety First to the new Before You Trip campaign focused on Gen Z and others newly exposed to psychedelics. Vilmarie Fraguda Narloch, PsyD (Director, Sana Healing Collective) will moderate a conversation between Kristin Nash, MPH (William G. Nash Foundation; Coalition for Psychedelic Safety and Education), Marsha Rosenbaum (Director Emerita, Drug Policy Alliance), and Ronan Wood to show how the Gen-Z-focused campaign uses data to inform sensible public health policy, taking another step toward a world with evidence-based drug education that actually keeps young people safer. Spiritual Gatekeeping: Navigating Faith and Law in Psychedelic Practice – What does it take to secure legal protection for sacred psychedelic practice? This session offers a first-hand look at the fight for religious exemptions, led by two lawyers at the forefront of this issue. Bob Jesse will moderate a panel with Taylor Loyden, whose client just received the first-ever exemption through the DEA's administrative process, and Martha Hartney, whose client settled with the federal government to secure its own religious rights just last year. These experts will unpack the current legal landscape under RFRA, draw on their direct experience working with the DEA and courts on behalf of psychedelic churches, and illuminate the precedents, pitfalls, and evolving policies that shape the landscape today. Going Forward: Challenging Misconceptions, Introducing Nuance, and Changing Public Opinion – Great ideas don't succeed on merit alone — winning public support is critical. In this data-driven session, researchers unveil fresh polling on American attitudes toward psychedelics and how strategic messaging can dispel stigma. Communication experts Matthew Goldberg, Ph.D. (Yale University) and Abel Gustafson, Ph.D. (University of Cincinnati) will present new survey findings showing what Americans really think about psychedelic therapy, where misconceptions run deepest, and which narratives are breaking through. They'll highlight which stories and statistics change minds, which demographics are most persuadable, and how advocacy groups can capitalize on shifting state by state. This session intends to offer attendees insights to build public support and momentum for policy change in their own context. Taking Responsibility through Restoration, Liberation, and 'Righter' Relationship – How can we participate in cultural renewal and collective liberation, even in the political sphere? Listen to two movement leaders answer this question by reflecting on their ongoing practice of weaving traditional ethical frameworks into psychedelic policy and the mainstream psychedelic community. Robert 'Roman' Haferd and Ariel Clark — seasoned lawyers of color and founding board members of the Psychedelic Bar Association — will report back from years of 'sensemaking' with dozens of BIPOC and Native land-based communities, reflect on the legal and ontological complexities of the psychedelic ecosystem, and invite the audience members to ask how existing systems can be utilized to center respect and responsibility toward our human and more-than-human relatives — including sacred plants. Visit to view the full schedule, register for workshops, and explore hotel and travel options. Workshop spaces are limited and available on a first-come basis. About Psychedelic Science Psychedelic Science 2025 (PS2025), hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), is the world's leading psychedelic conference. Returning to the Colorado Convention Center in Denver from June 16-20, 2025, this five-day event brings together a global community of scientists, therapists, policymakers, cultural leaders, and advocates to explore the forefront of psychedelic research, therapy, and culture. Facilitated by Superfly, known for iconic events such as Bonnaroo and Outside Lands, PS2025 will feature expert speakers; hands-on workshops; and community activities including art, music, and mindfulness. We are proud to have offered over a thousand scholarships to support broad participation across the community. Since its inception in 2010, the Psychedelic Science conference series has fostered knowledge-sharing, collaboration, and community-building within the psychedelic ecosystem. Join thousands of attendees as we explore the transformative potential of psychedelics and shape the future of mental health, policy, and cultural understanding. For more information and registration details, visit and follow us on X, Instagram, LinkedIn, and Facebook. ABOUT MAPS Founded in 1986, MAPS is a 501(c)(3) nonprofit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS' conference flagship, Psychedelic Science, has been the leading convening of the psychedelic community since 2010. MAPS incubated Lykos Therapeutics, a drug-development public benefit company, and the Zendo Project, a leader in psychedelic harm reduction. Since MAPS was founded, philanthropic donors and grantors have given more than $150 million to advance research, change drug policy, and evolve education in the field of psychedelics. CONTACT [email protected]
Associated Press
22-05-2025
- Health
- Associated Press
Ibogaine By David Dardashti to Share Groundbreaking Ibogaine Treatment Protocol Insights, Including for Neurodegenerative Conditions and Diabetes, at Psychedelic Science 2025 in Denver
DENVER, CO - May 21, 2025 - Ibogaine By David Dardashti, will be hosting a booth at the upcoming Psychedelic Science 2025 conference, hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS). The conference, a premier global gathering for psychedelic research, medicine, policy, and culture, will take place from June 16-20, 2025, at the Colorado Convention Center. Ibogaine By David Dardashti is expected to share profound insights into specific ibogaine treatment protocols tailored to diverse needs, a hallmark of his approach. This information will delve into the nuanced application of ibogaine for a range of conditions, including: Attendees will gain a precise understanding of the ramifications of these specific treatment lengths in relation to an individual's unique needs and circumstances. Dardashti will also illuminate the overall ibogaine experience, explaining its mechanisms and transformative potential with clarity and precision, particularly concerning its application beyond addiction to other challenging health conditions. Known for his work at Ibogaine by David Dardashti, he has long advocated for individualized care, emphasizing the importance of addressing the root causes of various ailments. His presence at Psychedelic Science 2025 offers a significant opportunity for clinicians, researchers, and the wider psychedelic community to learn about these structured and potentially pioneering approaches to ibogaine therapy. About David Dardashti: David Dardashti is a leading expert in ibogaine treatment with extensive experience in developing personalized protocols for addiction, psychological well-being, and other complex health conditions. About Psychedelic Science 2025: Psychedelic Science 2025, hosted by MAPS, is the leading international conference dedicated to the study of psychedelic substances for science, medicine, spirituality, and policy. It brings together experts from around the world to share the latest research and developments in the field. Media Contact Company Name: Ibogaine By David Dardashti Contact Person: Cole Barressi Email: Send Email Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Ibogaine By David Dardashti to Share Groundbreaking Ibogaine Treatment Protocol Insights, Including for Neurodegenerative Conditions and Diabetes, at Psychedelic Science 2025 in Denver
The Review Geek
21-05-2025
- Entertainment
- The Review Geek
Nine Perfect Strangers – Season 2 Episode 1 Recap & Review
Zauberwald Episode 1 of Nine Perfect Strangers season 2 starts with Masha invited up onto stage after her psychedelic therapy with Tranquillum has become a hit. At The end of season 1, we saw her driving off in a scene that felt very Cruel Intentions-esque, with her book Nine Perfect Strangers on the dashboard. Masha jokes about her multiple federal allegations, not shying away from what's happened, but also embracing her persona. She speaks to the crowd plainly about what she's been up to. Working with those in Silicon Valley, Masha has developed a new psychedelic delivery system to help patients revisit specific memories. Its been tested on rats and herself, but it hasn't been put out for public testing just yet. Masha also lies, claiming that she no longer sees her daughter, when she clearly does. She suffers from bad dreams, Tatiana is still in her peripheral vision, and her mental state is still not completely tip-top. It doesn't help that Masha has been hit with multiple subpoenas and she's struggling to stay afloat. Despite Masha's success in the States, she needs to get away from it all. Approached by a man named Martin, the head of Research and Protocol, Masha is encouraged to head over and run a new wellness centre in the Alps called Zauberwald. This place has significance to Masha's backstory, which we'll learn about in episode 2. For now, we learn that a woman called Helena calls the shots, who happens to be the individual responsible for introducing Masha to the psychedelic therapy that helped her see Tatiana initially. There are some ground rules laid out and it seems nobody here wants a repeat of the disaster over at Tranquillum. Much like the first seasin, we meet a bunch of different people who are going to be staying here on this transformative experience. Masha and her drugs are famous though so there's not going to be any psychedelic surprises – or so we're led to believe! Masha puts up a bunch of hidden cameras around the place, complete with mics. She also has far more control over the guests, including allowing everybody to keep their phones on them given the terrible cell signal up in the mountains. Masha has carefully curated the group for this retreat, each with their own desires and need for healing. There's Brian, a guy who's as clumsy as he is irritable and struggles with his bags. He runs into Sister Agnes staring blissfully into the horizon, whom he believes is a porter. She's actually a former nun but she keeps her cards close to her chest and it's unclear right now exactly why she's here. There's also Imogen who flaunts her intelligence and questions Martin over the project and overthinks everything. The reason she's here is to try and repair the relationship with her mum, Victoria. Unfortunately, Victoria is too busy with her new boytoy, Matteo. We also learn here too that Victoria has been divorced several times so it seems she has trouble with commitment. According to Masha and Helena though, Matteo is part of their 'plan'. Another couple that rock up are Tina and Wolfie who appear to have some demons clouding their relationship. They're both musicians but Tina appears top have lost her passion for playing the piano. She's also not particularly happy when she finds out Wolfie has set her up to go on this transformational retreat. She was under the assumption they were on vacation so it doesn't go over too well. Finally there's Peter, who rocks up and shares some banter with Imogen at the bar. He's actually due to meet his father here, who is also supposed to be part of this group. He's an eccentric billionaire by the name of David Sharpe, and he always puts his work ahead of family. As the guests flirt between letting their guard down or keeping their defences high, Imogen propositions Peter at the bar about staying in his room. As for Brian, he's got big mental issues, desperate to get his luggage back which appears to be lost. As the episode closes out, we get our first look at David Sharpe, who's intrigued by the prospect of these drugs 'turning him into a good person'. He's still sceptical though over whether they'll work or not. The Episode Review So Nine Perfect Strangers is back and the first episode wastes little time diving head-first into the same premise that season 1 had. This time we see a slightly different operation, in a different location, and a bit more clarity from the guests about why they're all here. There's clearly a lot of demons that need to be ironed out and Masha is at the forefront of this just like before, determined to disrupt the natural flow of everything and help the healing process. Interestingly, the end of season 1 saw Ben and Jessica in charge of Tranquillum and it's still not initially clear whether that will factor into this or not. The show is also quite quick in fast forwarding past Masha's issues and not spending much time exploring what this means for her career – or how much time has passed between seasons. What's here though is enticing enough, setting everything up for what should be a dramatic season to follow. Previous Season Next Episode Expect A Full Season Write-Up When This Season Concludes!
Yahoo
19-05-2025
- Business
- Yahoo
Reunion Neuroscience Announces Last Patient Dosed in RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
-- Enrollment Completed on Schedule; Topline Results Expected Q3 2025 -- -- Company to Present Poster Reviewing RE104 Phase 1 Results at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting on May 28, 2025 -- MORRISTOWN, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced the completion of patient enrollment and the last patient dosed in RECONNECT, a Phase 2 clinical trial evaluating RE104 in adult female patients with moderate-to-severe postpartum depression (PPD). Topline results from the study, which enrolled 84 patients, are anticipated in the third quarter of 2025. 'The completion of patient dosing in RECONNECT is a noteworthy accomplishment and reflects the significant enthusiasm from new mothers and their doctors for options that can offer rapid relief for the persistent depression and anxiety that characterizes PPD. Achieving this milestone on time and as planned per protocol also demonstrates the operational excellence of our team and clinical partners,' said Greg Mayes, President and Chief Executive Officer of Reunion. 'We look forward to reporting initial safety and efficacy data in the third quarter, which will provide key insights into RE104's potential as a fast-acting, short-duration psychedelic therapy for the treatment of PPD and other mental health disorders.' The RECONNECT Phase 2 clinical trial (NCT06342310) is a multicenter (38 clinical research sites in U.S.), randomized, double-blind, parallel-group, active dose-controlled clinical trial evaluating the safety and efficacy of a single subcutaneous dose of RE104. The trial was over-enrolled to include 84 adult female patients with moderate-to-severe PPD. The primary endpoint of the trial is the change from baseline at Day 7 in total Montgomery-Åsberg Depression Rating Scale (MADRS) score, a 10-item clinician-rated scale measuring depression severity. Key secondary endpoints include the change in MADRS at other timepoints, response rates (≥ 50% MADRS reduction), remission rates (MADRS ≤ 10), change in Hamilton Anxiety Rating Scale (HAM-A), Clinical Global Impression of severity and improvement, as well as overall safety and tolerability. Reunion will also evaluate RE104 for the treatment of adjustment disorder (AjD) in adult patients with cancer and other medical illnesses. The Company recently secured IRB approval and has initiated the site selection and activation process for REKINDLE, a randomized, double-blind, parallel-group, dose-controlled Phase 2 clinical trial evaluating the safety and efficacy of RE104 for AjD, and expects to enroll the first patient in mid-2025. ASCP Annual Meeting Poster Presentation Session: Reunion's Chief Medical Officer, Mark Pollack, M.D., will present a poster reviewing previously disclosed safety, pharmacokinetics (PK) and pharmacodynamics (PD) results from the first-in-human Phase 1 clinical trial of RE104 at the ASCP Annual Meeting, taking place May 27-30, 2025 in Scottsdale, AZ. In this Phase 1 trial, a single dose of RE104 was found to be safe and generally well tolerated, with robust PD effects and a short induced psychoactive state of approximately four hours, supporting the advancement of RE104 into the Phase 2 RECONNECT and REKINDLE trials. Details of the poster presentation session are as follows: Poster Title: RE104: A Novel Serotonergic Psychedelic 4-OH-DiPT Prodrug Date: May 28, 2025 Time: 11:15 a.m. MT (1:15 p.m. ET) About RE104The Company's lead product candidate, RE104, is a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT. Reunion designed RE104 to deliver a short psychedelic experience compared to longer experience duration with psychedelics like psilocybin or LSD. In a Phase 1 clinical trial, RE104 produced an acute psychedelic state similar in intensity and quality to psilocybin, but lasting only about half the time (3-4 hours), while demonstrating a similar, favorable safety profile. RE104 is currently being evaluated in the RECONNECT Phase 2 (NCT06342310) clinical trial, a multicenter, randomized, double-blind, active dose-controlled clinical trial in moderate-to-severe postpartum depression (PPD) patients. Initial data from RECONNECT are expected in the third quarter of 2025. Reunion plans to initiate the REKINDLE Phase 2 clinical trial, a randomized, double-blind, parallel-group, dose-controlled trial in adjustment disorder in cancer and other medical illnesses in mid-2025. About Reunion Neuroscience, Neuroscience is a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions. In 2023, Reunion became a private company and in 2024, the Company completed Series A financing co-led by MPM BioImpact and Novo Holdings. Reunion is actively investigating the use of its lead product candidate, RE104, in postpartum depression and adjustment disorder, as well as in additional neuropsychiatric indications where there remains a significant unmet need that is not addressed by the current standard of care. To learn more, visit and follow Reunion on LinkedIn and Bluesky. IR Inquiries:Hannah DeresiewiczPrecision PR Inquiries:Ashley Murphy Precision in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
